|
|
|
|
 |
|
|
|
Support EC OTC
EC (Emergency Contraception), or the “Morning-after Pill,” is a safe and effective method of preventing pregnancy up to five days after unprotected intercourse. Given it's time-sensitive nature, access to EC is imperative. Recent studies have indicated that wider access to EC could prevent 1.7 million unintended pregnancies and 800,000 abortions each year in the United States.
Despite its safety and potential benefits, the FDA ruled against the advice of its own expert panel, preventing EC from going over-the-counter. EC meets the FDA's own rigorous scientific criteria for over-the-counter access. This decision was not based on science, but rather on narrow political ideology. It is a major public health setback and a blow to women’s reproductive rights and health.
Write to the FDA today--let them know that you support EC over-the-counter! You can personalize your letter below.
Contact:
Lester Crawford (FDA Deputy Commissioner)
Mary Lewis (FDA Public Affairs Specialist for NC)
| Sample Letter for Campaign |
Subject: I support Emergency Contraception OTC
Dear [ Decision Maker ] ,
I write in support of making Emergency Contraception available over-the-counter.
Please stand up for women's health and reconsider Barr Laboratories' application for OTC status.
Sincerely,
|
Campaign Launched:
May 31, 2005
|
EC (Emergency Contraception), or the “Morning-after Pill,” is a safe and effective method of preventing pregnancy up to five days after unprotected intercourse. EC is often wrongly confused with RU-486, the abortion pill. EC is simply a super dose of birth control, and can only prevent pregnancy from occurring. It cannot terminate or harm an existing pregnancy.
EC is a time-sensitive drug—it is more effective in preventing pregnancy the sooner you take it. Thus, women’s access to EC is imperative. Recent studies have indicated that wider access to EC could prevent 1.7 million unintended pregnancies and 800,000 abortions each year in the United States.
Recently, in an unprecedented act, the FDA ruled against the advice of its own expert panel, preventing EC from going over-the-counter. EC meets the FDA's own rigorous scientific criteria for over-the-counter access. This decision was not based on science, but rather on narrow political ideology. It is a major public health setback and a blow to women’s reproductive rights and health.
|
|
|
|
|
|
|
|
|
|
plannedparenthood.org
